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What Regulatory Guidance Exists for Multipurpose 
Prevention Technologies (MPTs)?  A Review of Key 
Guidance Documents and Their Applicability to MPTs
By Martha Brady and Heeyoung Park
Building on its decades of support for developing contra-
ceptives as well as products to prevent sexually transmit-
ted infections (STIs), including HIV, the US Agency for 
International Development (USAID) is providing focused 
support to facilitate research and development, regula-
tory approval, and, ultimately, introduction of multipurpose 
prevention technologies (MPTs). 
As part of this effort, the Population Council is spear-
heading work to clarify and inform regulatory pathways 
for MPTs.  These are a unique and specialized subset of 
what regulatory authorities, including the US Food and 
Drug Administration (FDA), refer to as combination 
products.  The FDA, 21 CFR 3.2(e), defines combination 
products as “a product comprised of two or more regu-
lated components, any combination of a drug, device, and 
biological product, produced as a single entity.” 
Candidate products undergo review at the FDA 
depending on their designation, as follows:
Drugs: Center for Drug Evaluation and Research •	
(CDER)
Biologics: Center for Biologics Evaluation and •	
Research (CBER)
Devices and Radioactive Therapy: Center for Devices •	
and Radiological Health (CDRH)
Jurisdiction for review of combination products is deter-
mined by the Office of Combination Products (OCP) 
within the FDA, based on a given candidate’s Primary 
Mode of Action (PMOA).  The PMOA is the single mode of 
a combination product that provides the most important 
therapeutic action and is expected to make the greatest 
contribution to the overall intended effects of the prod-
uct.  The OCP is FDA-wide and makes its determinations 
about which sections of the agency to involve on a case-
by-case basis depending on the specifics of the proposed 
product.1 An important factor in the review of combination 
1Guidance for Industry and FDA Staff: “How to write a request 
of designation (RFD).” www.fda.gov/RegulatoryInformation/
Guidances/ucm126053.htm.
products is where the drug would fit within existing FDA 
structures. Some candidate multi-component drugs could 
be reviewed in one division of the FDA, while others may 
prompt review in two different divisions.
Review of Existing Guidance 
The Population Council conducted a systematic review of 
key guidance documents to determine whether and how 
they might apply to MPTs for sexual and reproductive 
health (SRH).  We developed a framework through which 
to review these documents, which included four key 
areas.  We asked whether the guidance: 
Encompasses “combination products”•	
Refers to both prevention and therapeutic products•	
Considers multi-indication products•	
Includes language and discussion of products for SRH •	
Searching through a broad range of guidance documents 
and guidelines from the FDA, European Medicines Agency 
(EMA), and International Conference on Harmonization 
of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH), we identified four 
documents which concern combination drug products, 
and thus might prove most relevant to MPTs.  We 
reviewed the following documents, all of which are in the 
public domain and available online: 
FDA/CDER—Guidance for Industry: Co-develop-•	
ment of Two or More Unmarketed Investigational 
Drugs for Use in Combination (draft Dec. 2010)2 
FDA/OCP—Guidance for Industry and FDA Staff: •	
Early Development Considerations for Innovative 





2    What Regulatory Guidance Exists for MPTs? 
EMA—Guideline on Clinical Development of Fixed •	
Combination Medicinal Products (Feb. 2009)4
ICH—Guidance on Nonclinical Safety Studies for •	
the Conduct of Human Clinical Trials and Market-
ing Authorization for Pharmaceuticals: M3R2 (June 
2009)5
Descriptions of Guidance Documents
Guidance for Industry: Co-development of  
Two or More Unmarketed Investigational  
Drugs for Use in Combination 
This guidance is intended to assist sponsors in the 
co-development of two or more novel (not previously 
marketed) drugs to be used in combination to treat a 
disease or condition. It provides recommendations and 
advice on how to address scientific and regulatory issues 
that will arise during co-development.  The FDA issued 
this guidance because the existing developmental and 
regulatory paradigm focuses primarily on assessment of 
the effectiveness and safety of a single new investigational 
drug acting alone, or in combination with an approved 
drug. Because co-development will generally provide less 
information about the safety and effectiveness of the 
individual drugs, it will present greater risk compared 
to development of an individual drug.  Therefore, the 
FDA believes that co-development should ordinarily be 
reserved for situations that meet the following criteria:  
The combination is intended to treat a serious dis-•	
ease or condition.
There is a compelling biological rationale for use of •	
the combination.
A preclinical model or short-term clinical study on •	
an established biomarker suggests that the combina-
tion has substantial activity and provides greater than 
additive activity or a more durable response com-
pared to the individual agents alone. 
There is a compelling reason for why the agents can-•	
not be developed individually. 
The guidance is not intended to apply to development of 
fixed-dose combinations of already marketed drugs or 
to development of a single new investigational drug to be 
used in combination with an approved drug(s). It is also 
not intended to apply to vaccines, gene or cellular thera-





Guidance for Industry and FDA Staff:  
Early Development Considerations for  
Innovative Combination Products 
This document provides guidance to industry and FDA 
staff on developmental considerations for innovative 
products that combine devices, drugs, and/or biological 
products. It is intended to provide a context for initial 
discussions on the type of scientific and technical informa-
tion that may be necessary for investigational or market-
ing applications for these combination products.  As with 
other medical products, combination product development 
typically focuses on the scientific and technical issues 
raised by the particular product being developed. For a 
combination product, these scientific/technical issues will 
ordinarily reflect the combination product itself as well 
as its constituent parts.  When combining products such 
as drugs or biologics and devices that are customarily 
developed using different regulatory paradigms, certain 
critical developmental issues, such as the interaction of the 
drug/biologic and device constituents, may not be readily 
apparent. Further, because of the breadth, innovation, and 
complexity of combination products, there is no single 
developmental paradigm appropriate for all combinations. 
The FDA recommends that developers consider the scien-
tific and technical issues raised by the combination product 
and its constituents, and propose an approach that appro-
priately addresses these issues without requiring duplica-
tive or redundant studies.  When the combination product 
is comprised of constituents that are chemically, physically, 
or otherwise combined or mixed and produced as a single 
entity, developers should consider and, as appropriate, 
evaluate the potential for a broad range of drug/biologic/
device interactions. For some combination products, the 
constituents may have synergistic effects that should be 
evaluated. In the context of these studies, it is appropriate 
to discuss approaches to avoid duplication/redundancy and 
to develop strategies to streamline the overlapping aspects 
of development.
EMA Guideline on Clinical Development of  
Fixed Combination Medicinal Products 
This guideline provides guidance on the clinical strategy to 
be considered when developing fixed combination medici-
nal products containing two or more active substances, 
which can be either well-known or not yet authorized 
in the European Union for the intended claim.  The 
development of fixed combination medicinal products 
will reflect the intended use (first- or second-line indica-
tion in patients inadequately controlled with individual 
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component(s) of the combination) and the intended indica-
tion (treatment of one disease or, for example, two closely 
related diseases, such as hyperlipidemia and hypertension, 
or substitution indication). Combination packs would only 
be acceptable in exceptional cases, when there would be 
clear public health benefits for the treatment regimen and/
or compliance, taking into account the required justifica-
tions. Potential advantages and disadvantages of fixed 
combinations are also discussed. 
ICH Guidance on Nonclinical Safety Studies  
for the Conduct of Human Clinical Trials and  
Marketing Authorization for Pharmaceuticals
A review of the ICH M3R2, section 17 provides additional 
guidance related to preclinical testing for combination 
products. Nonclinical toxicity testing is recommended 
for combinations.  The scope of the nonclinical testing on 
individual components is determined by whether those 
components are used as single entities (complete testing 
required for all individual entities and the combination) or  
used in a fixed-dose combination and not individually (only 
combination testing required).
Policy Analysis of Guidance:  
Application to MPTs for SRH
Our analysis of the existing guidance documents suggests 
that while they are generally useful starting points for con-
sidering the issues raised by the potential of MPTs, none 
of them applies specifically to MPTs for SRH. Further, these 
documents focus on therapeutic and single-indication 
combination products, not on prevention products per se. 
Below we provide a brief policy analysis of each document, 
and summarize in Table 1.  
The draft FDA guidance on co-development, describ-
ing the criteria for determining when co-development is 
an appropriate option, makes recommendations about 
nonclinical and clinical development strategies, and 
addresses certain regulatory process issues.  This guidance 
excludes fixed-dose combinations of already marketed 
drugs or development of a single new investigational drug 
to be used in combination with an approved drug(s).  And 
while this guidance points out that “further new thera-
peutic approaches using combinations of drugs directed at 
multiple therapeutic targets is needed to improve treat-
ment response or minimize development of resistance,” 
prevention products and multi-indications are not mentioned in 
the document.
The OCP guidance describes general principles to 
consider when developing information to demonstrate the 
safety and effectiveness of a combination product and its 
constituent parts. In the drug constituent considerations 
(section V-B), this guidance explains that a new molecular 
entity (NME) is a critical consideration in the combination 
product. For example, “certain conventional pharmacology 
and toxicology studies may be necessary to establish the 
safety profile of the NME alone before beginning clinical 
investigation of the combination product.”  This guidance 
focuses on providing considerations and perspectives on 
scientific and technical issues in early development of inno-
vative combination products, including drugs, biologics, and 
devices. It is quite general, and not specific to prevention drugs 
with multiple indications.  This guidance makes no mention of 
prevention products and multi-indications.
The guideline from the EMA is for fixed-dose com-
bination drug products, which define the combination of 
active substances within a single pharmaceutical form of 
administration.  An example of fixed-dose combination 
drugs is multiple antiretrovirals (ARVs) combined into a 
single pill, which helps reduce pill burden.  These guidelines 
mention prevention of disease for selecting doses of each 
substance, but the document focuses solely on therapeu-
tics.  While this guideline mentions multiple indications, it 
limits itself to treatment of one disease or two closely related 
diseases: “An indication must be a well-recognized disease 
state, or two closely related diseases, or a modification of 
a physiological or dysfunctional state, or a syndrome or 
pathological entity (section 6.1).  The individual substances 
of a fixed combination may be intended to relieve simulta-
neously different symptoms of such a disease state.”
Table 1  Analysis of Application of Existing Guidance to MPTs for SRH
Source of 
guidance
Includes information on 
“combination products”?
Refers to both therapeutic 
and prevention products? 




1 - CDER YES Therapeutic only NO NO
2 - OCP YES Therapeutic only NO NO
3 - EMA YES Both: however prevention is 
only mentioned in  
dosage proposal
YES, but only for “two closely 
related diseases such as hyperg-
lycemia & hypertension….”
NO
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Distilling the Complexity around  
Number and Type of Indications 
Given the range and diversity of products, the types and 
number of ingredients and indications, and the various 
FDA designations required for review, we developed a 
framework to illustrate and distill this complexity.  Table 2 
provides a summary of selected products, indications, and 
their FDA designation.  We have highlighted those which 
are already approved by the FDA, and are linked in some 
way to SRH (with exception of the combination vac-
cines).  There are a number of multi-indication products in 
clinical trials that could potentially be developed as an MPT. 
Next Steps
This review and analysis suggests several concrete next 
steps. First, we anticipate increased interaction with key 
regulatory agencies in the United States and abroad to 
help further clarify regulatory issues and challenges. Sec-
ond, drawing upon knowledge and experience in the area 
of combination products, along with work around acceler-
ated pathways, we will work with key individuals and insti-
tutions to develop a road map for regulatory pathways for 
MPTs. Finally, we hope this effort to understand and clarify 
regulatory processes will help the emerging field of MPTs. 





Product name Indication(s) FDA  
designation
Single product Single Copper T IUD Pregnancy prevention CDER




Pregnancy prevention, Rx heavy bleeding
Induce uterine contraction; prevention of postpartum 
hemorrhage
Prevention of gastric ulcer; induce uterine contraction 


















Multi-ingredient Multiple Multi-valent vaccines
Prevnar®
Gardasil®/Cervarix®
Prevention of invasive S. pneumoniae diseases
Prevention of HPV induced cervical, vulvar and rectal 
cancers, and genital warts
CBER
CBER





Prevention of diphtheria, tetanus, and pertussis (DTP)
Prevention of measles, mumps, and rubella
Prevention of polio, hepatitis B, and DTP
Prevention of polio, DTP, and invasive Haemophilus 
influenzae type b disease
CBER
CBER
CBER
CBER
